Qilian International Holding Group Limited (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, announced on Wednesday that it has received approval from Gansu Provincial Drug Administration for the sale of its newly developed nitrofurantoin enteric-coated tablets.
The tablets are intended to treat acute lower urinary tract infections caused by bacteria such as Escherichia coli, Enterococcus, Staphylococcus, Klebsiella, and Enterobacter. Nitrofurantoin enteric-coated tablets can also be used to prevent urinary tract infections and are commonly used as anti-inflammatory and bactericidal drugs.
Qilian's tablets have passed the on-site inspection and comprehensive assessment by the Examination and Inspection Center of the Gansu Provincial Drug Administration. As a result of the foregoing approvals, the firm's nitrofurantoin enteric-coated tablets have been determined by the applicable authorities to meet the national drug standards.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007